HEALTH CARE RESOURCE USE OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN SWEDEN

被引：0
|
作者：
Lauppe, R. [1 ]
Hansen, Liseth J. [1 ]
Fornwall, A. [1 ]
Gerdeskold, C. [2 ]
Rozenbaum, M. [3 ]
Strand, A. [4 ]
Vakevainen, M. [5 ]
Kuusisto, J. [6 ,7 ]
Gude, E. [8 ]
Gustafsson, F. [9 ]
Smith, J. G. [10 ]
机构：
[1] Quantify Res, Stockholm, Sweden
[2] Pfizer Innovat AB, Stockholm, Sweden
[3] Pfizer Inc, Capelle Aan Den Ijssel, Netherlands
[4] Pfizer ApS, Ballerup 84, Denmark
[5] Pfizer Oy, Helsinki, Finland
[6] Univ Eastern Finland, Kuopio, Finland
[7] Kuopio Univ Hosp, Kuopio, Finland
[8] Oslo Univ Hosp, Rikshosp, Oslo, Norway
[9] Rigshosp, Copenhagen, Denmark
[10] Lund Univ, Lund, Sweden
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB112
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [41] Racial and Genetic Differences Possible Health Disparities in Transthyretin Amyloid Cardiomyopathy Patients?
    Muller, Steven A.
    van der Meer, Manon G.
    Oerlemans, Marish I. F. J.
    JACC-HEART FAILURE, 2023, 11 (01) : 130 - 130
  • [42] Transthyretin Amyloid Cardiomyopathy Mimicking Hypertrophic Cardiomyopathy in an Older Patient
    Alves Guimaraes, Jose Pedro
    Trigo, Joana
    Goncalves, Fernando
    Ilidio Moreira, J.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 116 (04) : 850 - 853
  • [43] COMPASSIONATE DRUG USE FOR PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: THE FIRST EXPERIENCE IN ITALY
    Ciliberti, G.
    Torselletti, L.
    Barbarossa, A.
    Principi, S.
    Coraducci, F.
    Belleggia, S.
    Coretti, F.
    Bonci, A.
    Stronati, G.
    Casella, M.
    Dello Russo, A.
    Guerra, F.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25
  • [44] Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)
    Hanna, Mazen
    Damy, Thibaud
    Grogan, Martha
    Stewart, Michelle
    Gundapaneni, Balarama
    Patterson, Terrell A.
    Schwartz, Jeffrey H.
    Sultan, Marla B.
    Maurer, Mathew S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 141 : 98 - 105
  • [45] Exercise And The Development Of Transthyretin Amyloid Cardiomyopathy - Is There An Association?
    Aiken, Achilles V.
    Tso, Jason V.
    Patel, Nikhil J.
    Mersola, Savannah
    Vescio, Robert
    Patel, Jignesh
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S27 - S27
  • [46] Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05): : 505 - 505
  • [47] Tafamidis A Novel Treatment for Transthyretin Amyloid Cardiomyopathy
    Nawarskas, James J.
    Shephard, Emily A.
    CARDIOLOGY IN REVIEW, 2020, 28 (03) : 156 - 160
  • [48] Screening for transthyretin amyloid cardiomyopathy in everyday practice
    Pablo Garcia-Pavia, P.
    Bokhari, S.
    Damy, T.
    Elliott, P.
    Fine, N.
    Gospodinova, M.
    Obici, L.
    Rapezzi, C.
    Witteles, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 127 - 127
  • [49] The predicting system of prognosis for transthyretin amyloid cardiomyopathy
    Nakashima, N. N.
    Takashio, S. T.
    Morioka, M. M.
    Nishi, M. N.
    Hirakawa, K. H.
    Hanatani, S. H.
    Tsujita, K. T.
    EUROPEAN HEART JOURNAL, 2021, 42 : 875 - 875
  • [50] A NEW TRANSTHYRETIN MUTATION ASSOCIATED WITH AMYLOID CARDIOMYOPATHY
    SARAIVA, MJM
    ALMEIDA, MR
    SHERMAN, W
    GAWINOWICZ, M
    COSTA, P
    COSTA, PP
    GOODMAN, DS
    AMERICAN JOURNAL OF HUMAN GENETICS, 1992, 50 (05) : 1027 - 1030
12345